Jim Simons’s Dyne Therapeutics DYN Stock Holding History

Jim Simons’s Portfolio DYN Stock Details DYN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$9.67M	Buy	533,600 +62,955	+13%	+$1.09M	0.02%	985
2025 Q4	$9.21M	Buy	470,645 +125,145	+36%	+$2.37M	0.01%	958
2025 Q3	$4.37M	Buy	+345,500	New	+$3.94M	0.01%	1580
2024 Q3	–	Sell	-126,000	Closed	-$4.45M	–	3609
2024 Q2	$4.45M	Buy	+126,000	New	+$3.66M	0.01%	1378
2023 Q2	–	Sell	-73,300	Closed	-$844K	–	4005
2023 Q1	$844K	Sell	73,300 -34,400	-32%	-$447K	﹤0.01%	2584
2022 Q4	$1.25M	Buy	107,700 +2,800	+3%	+$32.4K	﹤0.01%	2397
2022 Q3	$1.33M	Buy	104,900 +13,700	+15%	+$157K	﹤0.01%	2315
2022 Q2	$627K	Buy	91,200 +48,500	+114%	+$334K	﹤0.01%	3017
2022 Q1	$412K	Sell	42,700 -25,800	-38%	-$220K	﹤0.01%	3302
2021 Q4	$814K	Sell	68,500 -72,000	-51%	-$1.01M	﹤0.01%	2798
2021 Q3	$2.28M	Buy	+140,500	New	+$2.49M	﹤0.01%	1986

Other funds holding DYN

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AVLSA

Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

FIS

FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return

Jim Simons's DYN Position: Q1 2026 in Review

Jim Simons increased its Dyne Therapeutics (DYN) stake by 13% in Q1 2026, buying an estimated $1.09M and bringing the position to 533,600 shares worth $9.67M. The position accounts for 0.02% of the portfolio, ranked #985.

Jim Simons first reported a position in DYN in Q3 2021 and has held it in 11 quarters since. 228 funds tracked by Wall St. Rank hold DYN as of Q1 2026.

Jim Simons held 533,600 shares of Dyne Therapeutics worth $9.67M as of Q1 2026.
Jim Simons bought 62,955 Dyne Therapeutics shares in Q1 2026, an estimated $1.09M.
Dyne Therapeutics made up 0.02% of Jim Simons's portfolio in Q1 2026, its #985 holding.
Jim Simons first reported a position in Dyne Therapeutics in Q3 2021 and has held it in 11 quarters since.
228 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q1 2026.

Based on Renaissance Technologies's 13F filing for Q1 2026, filed 14 May 2026.